Heart teams have several options when patients present with stable chest pain and require further testing. According to a brand new analysis of nearly 800 patients, CCTA may be the best place to start. 

New research out of Texas could go a long way toward improving care for patients with acute decompensated heart failure.

The FDA’s final decision was based largely on positive results from the ADVENT clinical trial, which compared treatment with the Farapulse PFA System to the current standard of care.

Annual SAVR volumes in the United States decreased by a whopping 44.5% from 2012 to 2022. However, heart teams across the country seem to agree that surgery is a safer, more effective treatment option than TAVR when patients present with bicuspid aortic valves. 

The two neighboring practices have joined forces to provide improved cardiovascular care for patients throughout the Sunshine State. 

Nearly 50% of patients under the age of 60 are now opting for TAVR over SAVR, according to a new study presented at STS 2024 in San Antonio. "We owe it to our patients to take a more prominent role in providing the highest quality evidence to help our patients make these major healthcare decisions," one researcher said. 

Paravalvular leak remains a significant problem after TAVR, SAVR and even TMVR. Could a new-look interventional technique help heart teams overcome this issue and improve patient outcomes? 

Performing two procedures at once does not appear to make a significant impact on patient safety, though it may lead to a few new risks sure to interest heart teams.